L-{GrAFT} and {EASE} scores in liver transplantation. Need for a reciprocal external validation and comparison with other scores by Avolio, Alfonso W. et al.
Several pathogens, such as Epstein–Barr, varicella-zoster, and
hepatitis Aviruses, can triggerAIHonset.4 In addition, some reports
described a relationship between vaccination (i.e., hepatitis A and
influenza virus) and the development of AIH,5–8 suggesting a
potential role of both virus and vaccine in unmasking AIH in
predisposed individuals. Thus, the occurrence of acute or chronic
liver disease following viral infection or vaccination should raise
the suspicionofAIH in thepresenceofotherautoimmunedisorders.
Although the causal link between the SARS-CoV-2 vaccine and
AIH cannot be definitively established, our case report suggests that
thisassociationcouldbemorethancoincidental. Indeed, themedical
historynegative for liverdiseaseaswellas thecoexistenceofanother
autoimmune disorder, the reasonable lag time between exposure to
the triggering factor, the typical onset of symptoms, the laboratory/
histopathological findings and finally the excellent response to
therapyareallpiecesof thepuzzle that reinforce thehypothesisof an
association between AIH and SARS-CoV-2 vaccination.
In summary, since the vaccination campaign against SARS-
CoV-2 is reaching extraordinary coverage rates, healthcare pro-
viders should be aware of the potential association between the
vaccine and the onset of immunomediated disorders in patients
with a history of autoimmune diseases.
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L-GrAFT and EASE scores in liver transplantation: Need for
reciprocal external validation and comparison with other scores
To the Editor:
We read with great interest the recent article by Agopian et al. on
the validation of the liver graft assessment following
transplantation (L-GrAFT) score for prediction of early allograft
failure (EAF).1 EAF was defined as the failure of the graft
(identified by retransplant or death) for any reason at 90 days
after liver transplantation.1,2 Adopting an innovative “kinetic”
approach which included calculation of the AUC and slope of
aspartate aminotransferase, bilirubin, platelet count, and
international normalized ratio (INR), the L-GrAFT1,2 was
reported to outperform both the model for early allograft
function (MEAF)3 and early allograft dysfunction (EAD)4 scores,
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namely the strongest validated scores available to date in this
setting. The authors used a cumulative retrospective database
from 4 North American (n = 3,201) and 7 European (n = 222)
large volume centers.1 The L-GrAFT has 2 calculation
modalities: at 7 days (L-GrAFT7) and at 10 days (L-GrAFT10).
Twenty-eight and 40 data entries are needed to calculate the
scores, respectively. Both L-GrAFT scores were validated in the
US cohort, while only the score at 7 days was validated in the
European cohort. For the L-GrAFT7, the authors report a C-sta-
tistic of 0.78 and 0.82 in the US and European cohort, respec-
tively. Unfortunately, calculation of L-GrAFT scores is rather
complex due to the significant number of requested data entries
and their estimation intrinsic nature. Moreover, dedicated soft-
ware is not yet available, and its logarithmic transformation does
not help daily use.
On these bases, we herein provide a counterpoint to L-GrAFT
offering additional evidence about early liver graft dysfunction
prediction. Starting from the seminal study by Agopian et al.,1 we
have recently validated the L-GrAFT10 on a population of 1,609
patients transplanted between 2016 and 2017 in 14 Italian
centers and obtained a C-statistic of 0.72.5 Using the original L-
GrAFT components, we have further refined and simplified the L-
GrAFT10 formula reducing the number of data entries from 40 to
17. The beta-coefficients were re-calculated, and additional donor
and recipient parameters were tested in 8 models. The final
comprehensive score for EAFassessment, namely the earlyallograft
failure simplified estimation (EASE) score, was internally validated
through bootstrap and externally validated on a UK database (2
centers, 570 patients). The characteristics of both databases and the
EASE-score formula are reported in Table S1 and S2, respectively.
Notably, the overall prevalence of grafts from donors after cardiac
death (DCD) and machine perfused (MP) grafts was 6.8% and
5.8%, respectively. Because neither of these categories were
significant predictors, EASE can also be used as a precise
algorithm to measure graft quality in translational studies that
include high-risk DCD and MP grafts.
Unlike L-GrAFT10, the EASE score does not include INR. Its AUC
and slope are based on a lower number of evaluations (4 vs. 10),
and no logarithmic transformation was used for bilirubin.
Furthermore, the EASE score includes the following, easy-to-be-
retrieved additional parameters: model for end-stage liver dis-
ease (MELD) score at transplant, number of intraoperatively
transfused packed red blood cells (PRBCs), hepatic vessel throm-
bosis on day 10, and center volume (>−70 or between 36 and 69
cases per year).
As a result, the EASE achieved a C-statistic of 0.87 (95% CI
0.83–0.91) in the derivation set and outperformed all previously
developed scores to predict EAF (Table 1).1–4,6–8With respect to the
comparison with the L-GrAFT (C-statistic 0.72; 95% CI 0.65–0.78),
the difference was significant using the DeLong test.9 Although
one could argue that a researcher-derived bias cannot be
excluded, we invite the L-GrAFT developers to test the EASE score
on both the North-American and COPE databases.
The EASE score also achieved an excellent C-statistic (0.93; 95%
CI 0.89–0.97) for prediction of EAF at 30 days and was further
validated in the UK cohort with a C-statistic of 0.78. Furthermore, it
allows for stratificationof liver grafts into 5 classes,with thehighest
one including cases to be referred for early retransplantation. The
online EASE-score calculator is available at
Listing a patient for retransplant is often challenging, and sur-
geons and transplant hepatologists are frequently reluctant in the
absence of objective signs of graft failure.10 In our opinion, the
inclusion of MELD, PRBCs, and hepatic vessel thrombosis is
essential for an innovative and comprehensive definition of EAF.
Notably, thrombosis of a hepatic vessel is a well-known indication
for early retransplant. However, medical and endovascular treat-
ments of thrombosis are nowmore efficacious than in the past, and
several patients without associated liver failure recover. From this
perspective, parenchymal and vascular causes of failure are linked
inan innovativedefinitionof EAF. Predictionof90-dayoutcomeand
early identificationofpatients inneedof retransplantation remaina
priority. The choice of the best algorithm requiresmultiple external
validation studies. A further step could be to design a prospective
international validation study to enroll a largernumberof cases and
include series from small-volume centers.
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Table 1. Comparison between EASE-score and other prognostic scores
predictive of EAF.*
C-statistic 95% CI p value
EASE score5 0.87 0.83–0.91
DRI8 0.53 0.46–0.59 <0.001
EAD4 0.70 0.63–0.75 <0.001
D-MELD6 0.60 0.54–0.67 <0.001
New ET-DRI7 0.55 0.49–0.62 <0.001
MEAF3 0.73 0.67–0.79 <0.001
L-GrAFT102 0.72 0.65–0.78 <0.001
DRI, Donor Risk Index; EAD, Early Allograft Dysfunction score; D-MELD, Donor age x
MELDscore;NewET-DRI, NewEuro-TransplantDonorRisk Index;MEAF,Model for Early
Allograft Failure score; L-GrAFT10, Liver Graft Assessment Following Transplantation.
EASE score shows the highest C-statistic at 90 days. The p values refer to the comparison
of the indicated score against EASE-score. EASE-score has a high discrimination ability
(absence of overlap of 95% CI between EASE score and other scores).
*ClinicalTrials.gov (NCT03858088).
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An unequivocal formula to calculate L-GrAFT score is needed
To the Editor:
We read with interest the article by Agopian et al. entitled:
“Multicenter validation of the liver graft assessment following
transplantation (L-GrAFT) score for assessment of early allograft
dysfunction”.1 Because early liver allograft dysfunction is difficult
to assess, L-GrAFT emerges as a promising tool to detect such
Table 1. An example of the impact of rounding of coefficients on risk estimates using the unrounded (L-GrAFT10 calculator provided in the supplement of
the Agopian et al. study1) and rounded coefficients.
Predictor Log OR OR Variable value Log OR rounded
Intercept 9.77
AUC log AST -0.429459177 0.650861 51.73551342 -0.429
AUC log AST, squared 0.004621305 1.004632 2676.563348 0.005
Slope log AST (early) 4.607190144 100.2022 -0.205468062 4.607
Slope log AST (early), squared 4.412900349 82.50842 0.042217125 4.413
Log max INR 0.889739754 2.434496 0.405465108 0.890
AUC log TBIL -0.04852114 0.9526372 22.36992196 -0.049
AUC log TBIL, squared 0.00362542 1.003632 500.4134084 0.004
Slope log TBIL 5.336266599 207.7357 -0.010094796 5.336
AUC log PLT -0.046205313 0.9548459 44.91034035 -0.046
Slope log PLT -5.248974974 0.0052529 0.171097045 -5.249
Slope log PLT squared 13.08633488 482306.4 0.029274199 13.086
L-GrAFT10 -2.39 With rounded factors: -1.17
Odds -> 0.09 0.31
Individualized risk 8.36% 23.68%
AST, aspartate aminotransferase; AUC, area under curve calculated as 10-day mean * 10; early slope, slope of linear regression of values in first 7 days post-transplant; INR,
international normalized ratio; OR, odds ratio; PLT, platelets; TBIL, total bilirubin.
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